Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Pfizer (NY: PFE )

29.07 -0.27 (-0.90%)
Streaming Delayed Price Updated: 2:51 PM EDT, Oct 11, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 20,386,476
Open 29.36
Bid (Size) 29.07 (42)
Ask (Size) 29.08 (54)
Prev. Close 29.34
Today's Range 28.95 - 29.44
52wk Range 25.20 - 33.92
Shares Outstanding 5,606,688,356
Dividend Yield 5.64%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Novo Nordisk, Eli Lilly Could Face Downward Pressure Despite Market Dominance From Potentially 16 New Obesity Drugs: See The Names
The $200B GLP-1 market is set to expand with 16 new obesity drugs launching by 2029, challenging Novo Nordisk and Eli Lilly's dominance while addressing scalability and pricing concerns. 
Via Benzinga
U.S. FDA Approves Pfizer’s HYMPAVZI™ (marstacimab-hncq) for the Treatment of Adults and Adolescents with Hemophilia A or B Without Inhibitors
From Pfizer Inc.
Via Business Wire

Performance

YTD
-2.20%
-2.20%
1 Month
-2.24%
-2.24%
3 Month
+1.45%
+1.45%
6 Month
+10.38%
+10.38%
1 Year
-12.19%
-12.19%

More News

Read More
Stock Market Rallies As S&P 500, Dow Hit Highs; Tesla Robotaxi Isn't Hailed, Delta, JPMorgan In Focus: Weekly Review
Via Investor's Business Daily
Topics Stocks
Exposures US Equities
(PFE) - Analyzing Pfizer's Short Interest
Via Benzinga
An Activist Investor Just Bought $1 Billion Worth of Pfizer. Here's What It Means for the Stock
Via The Motley Fool
Why Pfizer Stock Tumbled by Nearly 3% on Thursday
Via The Motley Fool
GSK, Pfizer Face Declining Respiratory Syncytial Virus Vaccine Sales Due To Narrow Age Recommendations
Via Benzinga
Personalized Treatment And Immunotherapy Are Pharma's Newest Weapons Against Cancer
Via Benzinga
What's Going On With Pfizer Stock On Thursday?
Via Benzinga
Pfizer Skids After Former Execs Flip On Activist Investor, Siding With CEO Albert Bourla
Via Investor's Business Daily
Pfizer’s TALZENNA® in Combination with XTANDI® Prolongs Overall Survival in Phase 3 TALAPRO-2 Trial
From Pfizer Inc.
Via Business Wire
2 No-Brainer Healthcare Stocks to Buy With $200 Right Now
Via The Motley Fool
Former Pfizer Executives Ian Read And Frank D'Amelio Support Albert Bourla's Leadership Amid Starboard Activism: 'Will Deliver Shareholder Value'
Via Benzinga
Why Pfizer Stock Popped Today
Via The Motley Fool
Pfizer Declares Fourth-Quarter 2024 Dividend
From Pfizer Inc.
Via Business Wire
Biden Administration Unveils Plan To Provide Generic Drugs for $2 to Medicare Recipients
Via Benzinga
S&P 500 Hits New All-Time High Ahead Of Fed Minutes As Lower Oil Prices Offer Relief: What's Driving Markets Wednesday?
Via Benzinga
Topics Economy Stocks
Exposures Interest Rates US Equities
Billionaire Ken Griffin Just Bought 7.9 Million Shares of This Beaten-Down Pharmaceutical Stock as It Eyes the Weight Loss Market
Via The Motley Fool
These 3 Stocks Just Spiked—Buy the Rally or Sell the News?
Via MarketBeat
As a Billionaire Activist Takes a Stake, Is Now the Time to Buy Pfizer Stock?
Via The Motley Fool
Pfizer CEO Albert Bourla Set To Meet Activist Investor Starboard Value As Pressure Mounts To Revitalize Struggling Stock: Report
Via Benzinga
Pfizer to Showcase Scientific Advancements in Respiratory and Other Infectious Diseases at IDWeek 2024
From Pfizer Inc.
Via Business Wire
Fifth Avenue Animate Launches New Website to Highlight Expertise in SaaS and Finance Video Marketing
Via Prodigy
Biotech Stocks Poised For Another Big Move In Q4
Via Talk Markets
Pfizer Wins London Court Battle, GSK's Respiratory Syncytial Virus Vaccine Patents Invalidated
Via Benzinga
Topics Intellectual Property
Exposures Intellectual Property
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.